GuidelineModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2024
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]).
Abstract readReviewPractice Guideline
In one paragraph
Guideline in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Self-supervised learning can distinguish myelodysplastic neoplasms from clinical mimics using bone marrow biopsies.Blood neoplasia · 2026Article
- A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions.Nature reviews. Clinical oncology · 2026Review
- A complete blood count-based machine learning model for rapid differentiation of aplastic anemia, immune thrombocytopenia, and myelodysplastic syndromes in routine clinical practice.Practical laboratory medicine · 2026Article
- Artificial intelligence reshaping the paradigm of hematologic malignancy diagnosis and treatment: From static assessment to dynamic precision management.Annals of hematology · 2026Review
- A diagnostic pitfall in iron-refractory microcytic hypochromic anemia with acquired ring sideroblasts initially treated as iron deficiency anemia-a case report.Frontiers in medicine · 2026Article
- Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.Current hematologic malignancy reports · 2025Review
- Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
53 authors.
Fnu AakashDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Pathology, University of Texas Medical Branch, Galveston, Texas.
Savanah D GisrielDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
Amer M ZeidanSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut.
John M BennettJames P. Wilmot Cancer Center, Division of Hematopathology, University of Rochester Medical Center, Rochester, New York.
Rafael BejarDivision of Hematology and Oncology, Moores Cancer Center, UC San Diego, La Jolla, California.
Jan Philipp BewersdorfDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Uma M BorateDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Jacqueline BoultwoodNuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
Andrew M BrunnerDivision of Hematology, Massachusetts General Hospital Brigham, Boston, Massachusetts.
Rena BucksteinDivision of Medical Oncology/Hematology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Hetty E CarrawayLeukemia Program, Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Jane E ChurpekDivision of Haematology, Oncology, and Palliative Care, Department of Medicine, Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
Naval G DaverDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
Amy E DeZernSidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland.
Fabio EfficaceHealth Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy.
Pierre FenauxService d'hématologie, Hôpital Saint-Louis (Assistance Publique Hôpitaux de Paris), Université de Paris-Cité, Paris, France.
Maria E FigueroaBiochemistry & Molecular Biology, Sylvester Comprehensive Cancer Center. University of Miami Miller School of Medicine, Miami, Florida.
Guillermo Garcia-ManeroDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
Steven D GoreCancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland.
Peter L GreenbergDivision of Hematology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Elizabeth A GriffithsRoswell Park Comprehensive Cancer Center, Buffalo, New York.
Stephanie HaleneSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut.
Christopher S HouriganFralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, District of Columbia.
Tae Kon KimDepartment of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
Nina KimNCI, NIH, Bethesda, Maryland.
Rami S KomrokjiMalignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Vijay K KutchrooBrigham and Women's Hospital, Boston, Massachusetts.
Alan F ListChief Scientific Officer, Stelexis Therapeutics, New York, New York.
Richard F LittleCancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland.
Ravindra MajetiDivision of Hematology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Aziz NazhaDepartment of Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Stephen D NimerDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Olatoyosi OdenikeLeukemia Program, Section of Hematology/Oncology, University of Chicago Medicine and University of Chicago Comprehensive Cancer Center, Chicago, Illinois.
Eric PadronMalignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Mrinal M PatnaikDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Uwe PlatzbeckerDepartment of Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.
Matteo G Della PortaIRCCS Humanitas Research Hospital, Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Gail J RobozWeill Cornell Medical College and New York Presbyterian Hospital, New York, New York.
David A SallmanMalignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Valeria SantiniMyelodysplastic Syndromes Unit, Department of Experimental and Clinical Medicine, Hematology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy.
Guillermo SanzHealth Research Institute La Fe, Valencia, Spain; Hospital Universitario y Politécnico La Fe, Valencia, Spain; CIBERONC, IS Carlos III, Madrid, Spain.
Michael R SavonaDepartment of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
Mikkael A SekeresDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Maximilian StahlDepartment of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Daniel T StarczynowskiDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital, Cincinnati, Ohio.
David P SteensmaDavid Steensma LLC, Cambridge, Massachusetts.
Justin TaylorDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Omar Abdel-WahabDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Andrew H WeiDepartment of Haematology, Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Victoria, Australia.
Zhuoer XieMalignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Mina L XuDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut.
Robert P HasserjianDepartment of Pathology, Massachusetts General Hospital Brigham, Boston, Massachusetts.
Sanam LoghaviDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: Sloghavi@mdanderson.org.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MThe Memorial Sloan Kettering Cancer Center SPORE in LeukemiaP50CA254838 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Eytan Stein · 2021 to 2026
$16.8MNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA254838
Abstract
Myelodysplastic neoplasms/syndromes (MDS) are a heterogeneous group of biologically distinct entities characterized by variable degrees of ineffective hematopoiesis. Recently, 2 classification systems (the 5th edition of the World Health Organization Classification of Haematolymphoid tTumours and the International Consensus Classification) further subcharacterized MDS into morphologically and genetically defined groups. Accurate diagnosis and subclassification of MDS require a multistep systemic approach. The International Consortium for MDS (icMDS) summarizes a contemporary, practical, and multimodal approach to MDS diagnosis and classification.
Indexed as
Myelodysplastic SyndromesHumansclassificationdiagnosisicMDSMDSmyelodysplastic neoplasmsmyelodysplastic syndromes
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.